Conatus Pharmaceuticals (CNAT) seems it might be good as well. But one I'm looking at is LaJolla Pharmaceuticals (LJPC) where they got positive results in phase 2a of chronic kidney disease and have seen good results in NASH in pre-clinical trial.

I like this article because it holds true after all the retail stores and other systems getting hacked. Although some blame can be attributed to the fact that some of these companies don't want to put up the big money to secure their networks more as they should.

I love Benitec Biopharma as well with Rxi Pharmaceuticals because they both trade at low market cap value and work with RNAi oligonucleotides. Although Benitec uses the ddRNAi technology basically DNA derived with RNAi to send through the body to the targeted cell. Although the company needs to advance their drug more as they have only recruited like a few people in their Hep C trial. Still for speculation play Benitec Biopharma is good as well. Nice article!

It's a huge deal and I think Allergan BOD did well getting the price they wanted. Plus they didn't want to sell to Valeant and Pershing Square.

When do the banks not have criminal problems. But like always they get a slap on the wrist with a small fine and then move on to their normal business.

Disney is amazing! The CEO knows what he is doing to create value for the company as he has already acquired the Star Wars series and has been expanding upon the franchise. I think that Disney still has a long way to go up in share price.

Buying Back Shares won't do much for IBM they need to really figure out what they are going to do with the future of the company as revenue has been a disaster lately. The CEO needs to find a new direction and establish it soon or else the stock will continue its decline.

yes Gilead will be fine for quite some time with Sovaldi revenue. Although eventually they need to advance other products in pipeline as hepatitis C space fills up quickly.

I think Gilead will easily beat once again as Sovaldi is gonna help boost their earnings once more. Although Gilead will still need to work on additional products in the pipeline as the Hepatitis C space will eventually be crowded. As for Facebook I think it will beat earnings as they have been doing a good job growing the company with ad revenues.

I would pick Tekmira Pharmaceuticals and Inovio Pharmaceuticals as the two leading runners because both of their technologies is what will change medicine for a long time. Tekmira is working with RNAi-- RNA interference -- so that's a new science that is making strides to knock down the genes of diseases before a protein of that disease is ever made.

As for Inovio they have found a great method to increase efficacy of DNA vaccines by using an electroporation device that unfolds cells temporarily so that Inovio's Synthetic DNA vaccine antigen can enter the cell quickly before the cell closes back up. If I had to choose two companies for Ebola outbreak I would chose those, plus the fact that their pipelines are even bigger than imagined.